



Lin Zhang, M.D., Ph.D.

Clinical Interests	Dr. Zhang's clinical and research interests focus primarily on Parkinson's disease, including its epidemiology and the association between past nutritional deficiency and current prevalence of the disease. He is testing new drugs with neuroprotective properties that may slow down the progression of Parkinson's. Dr. Zhang also specializes in functional neurology focusing on the implantation and management of deep brain stimulation. He is investigating the clinical manifestation of the disease in patients with atypical Parkinson's disease, and those with a family history of pre-mutation for fragile X syndrome, a genetic disorder that typically affects children. Additionally, Dr. Zhang specializes in botulinum toxin (Botox) treatments for a variety of conditions, including, but not limited to, dystonia, spasticity and tremor. He uses electric muscle testing when giving Botox injections to improve accuracy and gain maximal results.
Title	Associate Professor
Specialty	Neurology
Department	Neurology
Division	Neurology UC Davis Medical Group, Sacramento - Midtown
Address/Phone	UC Davis Midtown Ambulatory Care Center, Midtown Neurology Clinic, 3160 Folsom Blvd Suite 2100 Sacramento, CA 95816 Phone: 916-734-3588
Additional Phone	Clinic Phone: 916-734-3588 Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Languages	Chinese (Mandarin)
Education	M.D., Beijing University School of Medicine, Beijing, 1984 Ph.D., Tulane University, New Orleans, Louisiana, 1994
Internships	Beijing Hospital, Beijing, China, 1983-1985 Cleveland Clinic Foundation, Cleveland, Ohio, 1994-1995
Residency	Beijing Hospital, Beijing, China, 1983-1985 Cleveland Clinic Foundation, Cleveland, Ohio, 1995-1998
Fellowships	University of Rochester, Rochester, New York, 1998-2000



Lin Zhang, M.D., Ph.D.

Professional Memberships

American Academy of Neurology
Movement Disorders Society

Honors and Awards

Roche Movement Disorders Research Award, 1997

Select Recent Publications

Disbrow EA, Russo KA, Higginson CI, Yund EW, Ventura MI, Zhang L, Malhado-Chang N, Woods DL, Sigvardt KA. Efficacy of tailored computer-based neurorehabilitation for improvement of movement initiation in Parkinson's disease. *Brain Res.* 2012 May 3;1452:151-64. Epub 2012 Mar 9.

Hamlin A, Liu Y, Nguyen DV, Tassone F, Zhang L, Hagerman RJ. Sleep apnea in fragile X premutation carriers with and without FXTAS. *Am J Med Genet B Neuropsychiatr Genet.* 2011 Dec;156B(8):923-8. doi: 10.1002/ajmg.b.31237. Epub 2011 Sep 19.

Adams PE, Adams JS, Nguyen DV, Hessel D, Brunberg JA, Tassone F, Zhang W, Koldewyn K, Rivera SM, Grigsby J, Zhang L, Decarli C, Hagerman PJ, Hagerman RJ. Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. *Am J Med Genet B Neuropsychiatr Genet.* 2010 Apr 5;153B(3):775-85.

Lua LL, Zhang L. Development of Parkinsonism following exposure to aripiprazole: two case reports. *J Med Case Reports.* 2009 Mar 10;3:6448.

Zhang L, Coffey S, Lua LL, Greco CM, Schafer JA, Brunberg J, Borodyanskaya M, Agius MA, Apperson M, Leehey M, Tartaglia N, Tassone F, Hagerman PJ, Hagerman RJ. FMR1 premutation in females diagnosed with multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 2009 Jul;80(7):812-4.

Leehey MA, Berry-Kravis E, Goetz CG, Zhang L, Hall DA, Li L, Rice CD, Lara R, Cogswell J, Reynolds A, Gane L, Jacquemont S, Tassone F, Grigsby J, Hagerman RJ, Hagerman PJ. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. *Neurology.* 2008 Apr 15;70(16 Pt 2):1397-402. Epub 2007 Dec 5.

Hagerman RJ, Hall DA, Coffey S, Leehey M, Bourgeois J, Gould J, Zhang L, Seritan A, Berry-Kravis E, Olichney J, Miller JW, Fong AL, Carpenter R, Bodine C, Gane LW, Rainin E, Hagerman H, Hagerman PJ. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. *Clin Interv Aging.* 2008;3(2):251-62. Review.

Hagerman RJ, Coffey SM, Maselli R, Soontarapornchai K, Brunberg JA, Leehey MA, Zhang L, Gane LW, Fenton-Farrell G, Tassone F, Hagerman PJ. Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome. *Am J Med Genet A.* 2007 Oct 1;143A(19):2256-60.

Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, Grigsby J, Bourgeois JA, Finucane B, Jacquemont S, Brunberg JA, Zhang L, Lin J, Tassone F, Hagerman PJ, Hagerman RJ, Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing



Lin Zhang, M.D., Ph.D.

guidelines. *Mov Disord*. 2007 Oct 31;22(14):2018-30, quiz 2140.

Adams JS, Adams PE, Nguyen D, Brunberg JA, Tassone F, Zhang W, Koldewyn K, Rivera SM, Grigsby J, Zhang L, DeCarli C, Hagerman PJ, Hagerman RJ. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). *Neurology*. 2007 Aug 28;69(9):851-9.

© 2017 UC Regents